ICU Medical Q4 Earnings Call Highlights

On expenses, Bonnell reported adjusted SG&A of $113 million and adjusted R&D of $21 million, with total adjusted operating expenses of $134 million, or 25% of revenue. He said operating expenses came in a half point below prior guidance, citing deferred spending and general cost controls. Restructuring, integration, and strategic transaction expenses were $20 million in the quarter, tied primarily to IT systems integration and manufacturing plant consolidation projects, where spending “peaked in Q4” as proj ...